Detection of somatostatin receptors in human osteosarcoma
- PMID: 18783595
- PMCID: PMC2546404
- DOI: 10.1186/1477-7819-6-99
Detection of somatostatin receptors in human osteosarcoma
Abstract
Background: The location of osteosarcoma in the metaphysis as well as the age of the patients during the most rapid tumour growth suggest that factors related to skeletal growth are involved in the pathogenesis of this tumour. In this aspect this study aims to detect somatostatin receptors in human osteosarcomas and correlate this finding with the clinical outcome of the tumour.
Patients and methods: Immunohistochemical staining for the presence of somatostatin receptors as well as overall survival and disease free survival rates were retrospectively studied in twenty-nine osteosarcoma patients.
Results: Four osteosarcomas with several aggressive biologic behaviour expressed somatostatin receptors. In these four young patients the event free rate was 0% and the overall survival rate was 50% at 4, 3 years. In contrast the event free survival rate of the twenty-five patients with negative somatostatin receptor status was 72% with an overall survival rate of 76% at 4,3 years.
Conclusion: The present study demonstrates the existence of somatostatin receptors in human osteosarcoma. Tumours expressing somatostatin receptors seemed to be aggressive with a very low disease free and overall survival rate compared to osteosarcoma with negative receptor status.
Figures


Similar articles
-
Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker.J Clin Pathol. 2007 Jul;60(7):804-7. doi: 10.1136/jcp.2005.032839. Epub 2006 Oct 3. J Clin Pathol. 2007. PMID: 17018686 Free PMC article.
-
Ezrin expression predicts survival in stage IIB osteosarcomas.Clin Orthop Relat Res. 2007 Jun;459:229-36. doi: 10.1097/BLO.0b013e3180413dbf. Clin Orthop Relat Res. 2007. PMID: 17353802
-
Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.Pediatr Blood Cancer. 2008 Apr;50(4):752-6. doi: 10.1002/pbc.21360. Pediatr Blood Cancer. 2008. PMID: 17886294
-
A preliminary investigation of Beta-hCG expression in patients with osteosarcoma.J Bone Joint Surg Br. 2012 Mar;94(3):419-24. doi: 10.1302/0301-620X.94B3.27679. J Bone Joint Surg Br. 2012. PMID: 22371553 Review.
-
A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma.Eur J Cancer Care (Engl). 2010 May;19(3):313-6. doi: 10.1111/j.1365-2354.2008.00970.x. Epub 2009 Aug 26. Eur J Cancer Care (Engl). 2010. PMID: 19709164 Review.
Cited by
-
Sarcoma arising as a distinct nodule within glioblastoma: a morphological and molecular perspective on gliosarcoma.J Neurooncol. 2011 Nov;105(2):317-23. doi: 10.1007/s11060-011-0593-6. Epub 2011 May 1. J Neurooncol. 2011. PMID: 21533839
-
Imaging and treatment with 68Gallium and 177Lutetium-DOTATATE in a rare SSTR2 and ESWR1-CREM fusion positive undifferentiated round cell tumour of the lung.BJR Case Rep. 2022 Nov 8;9(1):20220094. doi: 10.1259/bjrcr.20220094. eCollection 2023 Feb. BJR Case Rep. 2022. PMID: 36873236 Free PMC article.
-
Ga-68 DOTATATE PET/CT in the Evaluation of Paragangliomas and Other Indeterminate Lesions in the Head and Neck.Indian J Nucl Med. 2022 Oct-Dec;37(4):350-358. doi: 10.4103/ijnm.ijnm_66_22. Epub 2022 Dec 2. Indian J Nucl Med. 2022. PMID: 36817195 Free PMC article.
References
-
- Campanacci M. Bone and soft tissue tumors: clinical features, imaging, pathology and treatment. 2. Padova: Wein: Springer-Verlag; 1999.
-
- Huvos AG. Bone tumors: diagnosis, treatment and prognosis. 2. Philadelphia; London: W.B. Saunders; 1991.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical